|
1
|
Rubin BP, Heinrich MC and Corless CL:
Gastrointestinal stromal tumour. Lancet. 369:1731–1741. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Corless CL, Barnett CM and Heinrich MC:
Gastrointestinal stromal tumours: origin and molecular oncology.
Nat Rev Cancer. 11:865–878. 2011.PubMed/NCBI
|
|
5
|
D'Amato G, Steinert DM, McAuliffe JC and
Trent JC: Update on the biology and therapy of gastrointestinal
stromal tumors. Cancer Control. 12:44–56. 2005.PubMed/NCBI
|
|
6
|
Joensuu H, Hohenberger P and Corless CL:
Gastrointestinal stromal tumour. Lancet. 382:973–983. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Joensuu H and DeMatteo RP: The management
of gastrointestinal stromal tumors: a model for targeted and
multidisciplinary therapy of malignancy. Annu Rev Med. 63:247–258.
2012. View Article : Google Scholar :
|
|
8
|
Heinrich MC, Corless CL, Blanke CD,
Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M,
Fletcher CD, Sandau K, et al: Molecular correlates of imatinib
resistance in gastrointestinal stromal tumors. J Clin Oncol.
24:4764–4774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lim KH, Huang MJ, Chen LT, Wang TE, Liu
CL, Chang CS, Liu MC, Hsieh RK and Tzen CY: Molecular analysis of
secondary kinase mutations in imatinib-resistant gastrointestinal
stromal tumors. Med Oncol. 25:207–213. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hou XW, Bai CG, Liu XH, Qiu C, Huang L, Xu
JJ and Ma DL: Expression of stem cell factor in gastrointestinal
stromal tumors: implications for proliferation and imatinib
resistance. Oncol Lett. 5:552–558. 2013.PubMed/NCBI
|
|
11
|
Rutkowski P, Symonides M, Zdzienicki M and
Siedlecki JA: Developments in targeted therapy of advanced
gastrointestinal stromal tumors. Recent Patents Anticancer Drug
Discov. 3:88–99. 2008. View Article : Google Scholar
|
|
12
|
Kalkhoven E: CBP and p300: HATs for
different occasions. Biochem Pharmacol. 68:1145–1155. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Giordano A and Avantaggiati ML: p300 and
CBP: partners for life and death. J Cell Physiol. 181:218–230.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Goodman RH and Smolik S: CBP/p300 in cell
growth, transformation, and development. Genes Dev. 14:1553–1577.
2000.PubMed/NCBI
|
|
15
|
Santer FR, Höschele PP, Oh SJ, Erb HH,
Bouchal J, Cavarretta IT, Parson W, Meyers DJ, Cole PA and Culig Z:
Inhibition of the acetyltransferases p300 and CBP reveals a
targetable function for p300 in the survival and invasion pathways
of prostate cancer cell lines. Mol Cancer Ther. 10:1644–1655. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bandyopadhyay D, Okan NA, Bales E,
Nascimento L, Cole PA and Medrano EE: Down-regulation of p300/CBP
histone acetyltransferase activates a senescence checkpoint in
human melanocytes. Cancer Res. 62:6231–6239. 2002.PubMed/NCBI
|
|
17
|
Gao XN, Lin J, Ning QY, Gao L, Yao YS,
Zhou JH, Li YH, Wang LL and Yu L: A histone acetyltransferase p300
inhibitor C646 induces cell cycle arrest and apoptosis selectively
in AML1-ETO-positive AML cells. PLoS One. 8:e554812013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Papoutsopoulou S and Janknecht R:
Phosphorylation of ETS transcription factor ER81 in a complex with
its coactivators CREB-binding protein and p300. Mol Cell Biol.
20:7300–7310. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Baena E, Shao Z, Linn DE, Glass K, Hamblen
MJ, Fujiwara Y, Kim J, Nguyen M, Zhang X, Godinho FJ, et al: ETV1
directs androgen metabolism and confers aggressive prostate cancer
in targeted mice and patients. Genes Dev. 27:683–698. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Goel A and Janknecht R:
Acetylation-mediated transcriptional activation of the ETS protein
ER81 by p300, P/CAF, and HER2/Neu. Mol Cell Biol. 23:6243–6254.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chi P, Chen Y, Zhang L, Guo X, Wongvipat
J, Shamu T, Fletcher JA, Dewell S, Maki RG, Zheng D, et al: ETV1 is
a lineage survival factor that cooperates with KIT in
gastrointestinal stromal tumours. Nature. 467:849–853. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhang Y, Gu ML, Zhou XX, Ma H, Yao HP and
Ji F: Altered expression of ETV1 and its contribution to
tumorigenic phenotypes in gastrointestinal stromal tumors. Oncol
Rep. 32:927–934. 2014.PubMed/NCBI
|
|
23
|
Bowers EM, Yan G, Mukherjee C, Orry A,
Wang L, Holbert MA, Crump NT, Hazzalin CA, Liszczak G, Yuan H, et
al: Virtual ligand screening of the p300/CBP histone
acetyltransferase: identification of a selective small molecule
inhibitor. Chem Biol. 17:471–482. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cohen MH, Farrell A, Justice R and Pazdur
R: Approval summary: imatinib mesylate in the treatment of
metastatic and/or unresectable malignant gastrointestinal stromal
tumors. Oncologist. 14:174–180. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Judson I and Demetri G: Advances in the
treatment of gastrointestinal stromal tumours. Ann Oncol. 18(Suppl
10): x20–x24. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Demetri GD, van Oosterom AT, Garrett CR,
Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich
MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients
with advanced gastrointestinal stromal tumour after failure of
imatinib: a randomised controlled trial. Lancet. 368:1329–1338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lee JH, Kim Y, Choi JW and Kim YS:
Correlation of imatinib resistance with the mutational status of
KIT and PDGFRA genes in gastrointestinal stromal tumors: a
meta-analysis. J Gastrointestin Liver Dis. 22:413–418.
2013.PubMed/NCBI
|
|
28
|
Tarn C, Rink L, Merkel E, Flieder D,
Pathak H, Koumbi D, Testa JR, Eisenberg B, von Mehren M and Godwin
AK: Insulin-like growth factor 1 receptor is a potential
therapeutic target for gastrointestinal stromal tumors. Proc Natl
Acad Sci USA. 105:8387–8392. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Koelz M, Lense J, Wrba F, Scheffler M,
Dienes HP and Odenthal M: Down-regulation of miR-221 and miR-222
correlates with pronounced Kit expression in gastrointestinal
stromal tumors. Int J Oncol. 38:503–511. 2011. View Article : Google Scholar
|
|
30
|
Ionov Y, Matsui S and Cowell JK: A role
for p300/CREB binding protein genes in promoting cancer progression
in colon cancer cell lines with microsatellite instability. Proc
Natl Acad Sci USA. 101:1273–1278. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ianculescu I, Wu DY, Siegmund KD and
Stallcup MR: Selective roles for cAMP response element-binding
protein binding protein and p300 protein as coregulators for
androgen-regulated gene expression in advanced prostate cancer
cells. J Biol Chem. 287:4000–4013. 2012. View Article : Google Scholar :
|
|
32
|
Bayly R, Chuen L, Currie RA, Hyndman BD,
Casselman R, Blobel GA and LeBrun DP: E2A-PBX1 interacts directly
with the KIX domain of CBP/p300 in the induction of proliferation
in primary hematopoietic cells. J Biol Chem. 279:55362–55371. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kung AL, Rebel VI, Bronson RT, Ch'ng LE,
Sieff CA, Livingston DM and Yao TP: Gene dose-dependent control of
hematopoiesis and hematologic tumor suppression by CBP. Genes Dev.
14:272–277. 2000.PubMed/NCBI
|
|
34
|
Kawasaki H, Eckner R, Yao TP, Taira K,
Chiu R, Livingston DM and Yokoyama KK: Distinct roles of the
co-activators p300 and CBP in retinoic-acid-induced F9-cell
differentiation. Nature. 393:284–289. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rubin BP: Bioinformatic mining of gene
expression datasets identifies ETV1 as a critical regulator of
oncogenesis in gastrointestinal stromal tumors. Cancer Cell.
18:407–408. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Dhillon AS, Hagan S, Rath O and Kolch W:
MAP kinase signalling pathways in cancer. Oncogene. 26:3279–3290.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Duensing A, Medeiros F, McConarty B,
Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD and
Fletcher JA: Mechanisms of oncogenic KIT signal transduction in
primary gastrointestinal stromal tumors (GISTs). Oncogene.
23:3999–4006. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wang D, Lu J, Liu Y, Meng Q, Xie J, Wang Z
and Teng L: Liquiritigenin induces tumor cell death through
mitogen-activated protein kinase- (MPAKs-) mediated pathway in
hepatocellular carcinoma cells. Biomed Res Int.
2014:9653162014.PubMed/NCBI
|
|
39
|
Yoon JY, Cho HS, Lee JJ, Lee HJ, Jun SY,
Lee JH, Song HH, Choi S, Saloura V, Park CG, et al: Novel TRAIL
sensitizer Taraxacum officinale F.H. Wigg enhances TRAIL-induced
apoptosis in Huh7 cells. Mol Carcinog. 55:387–396. 2016. View Article : Google Scholar
|
|
40
|
Kuo KL, Ho IL, Shi CS, Wu JT, Lin WC, Tsai
YC, Chang HC, Chou CT, Hsu CH, Hsieh JT, et al: MLN4924, a novel
protein neddylation inhibitor, suppresses proliferation and
migration of human urothelial carcinoma: in vitro and in vivo
studies. Cancer Lett. 363:127–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Krestnikova N, Stulpinas A, Imbrasaite A,
Sinkeviciute G and Kalvelyte AV: JNK implication in adipocyte-like
cell death induced by chemotherapeutic drug cisplatin. J Toxicol
Sci. 40:21–32. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Bolden JE, Peart MJ and Johnstone RW:
Anticancer activities of histone deacetylase inhibitors. Nat Rev
Drug Discov. 5:769–784. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mühlenberg T, Zhang Y, Wagner AJ,
Grabellus F, Bradner J, Taeger G, Lang H, Taguchi T, Schuler M,
Fletcher JA, et al: Inhibitors of deacetylases suppress oncogenic
KIT signaling, acetylate HSP90, and induce apoptosis in
gastrointestinal stromal tumors. Cancer Res. 69:6941–6950. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Patel S: Exploring novel therapeutic
targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol
Rep. 15:386–395. 2013. View Article : Google Scholar : PubMed/NCBI
|
